Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Notice of Special Interest (NOSI): Leveraging glial cells to treat addiction

National Institutes of Health

This Notice of Special Interest (NOSI) encourages studies to exploit the unique properties and functions of glial cells and develop strategies to mitigate Central Nervous System (CNS) damage due to acute or chronic exposure to addictive substances or therapeutic avenues for addiction treatments.

Examples of research topic to facilitate the use of glia as therapeutic targets are described in the following categories. Areas of interest include, but are not limited to:

Glia-directed pharmacotherapies for addiction treatments. Glia express several sub-types of dopamine receptors, multiple members of the G protein-coupled receptor (GPCR) super-family, calcium channels, and voltage-gated ion channels that are critical regulators of dopaminergic signaling in the brain reward system. Generating viable SUD treatments that leverage glial cells requires identifying the molecular targets of specific populations of glial cells.

Conversion of glia to neurons for SUD therapy. Emerging studies have demonstrated glia can be reprogrammed into functional neurons in defined brain regions. These approaches are promising for treating various aspects of neurological disorders including SUD, although more work is needed to describe discrete cellular identities and functional features of the glial-derived neurons in their respective circuits.

Cell-cell interaction approach. Acting as architects of the CNS, astrocytes and microglia are involved in synapse formation and clearance, both during and post-development. Oligodendrocytes have major roles in shaping synapse formation, neuronal circuit development, and myelination. Therapeutic applications in SUD that modify interactions between neurons and glia to regulate different synaptic classes in different brain regions in vivo will be a key area of exploration. Approaches such as engineering the cell surface to display functional modules, tools that can fabricate and manipulate cell assemblies and control cell-cell interactions may be explored to advance this area.

This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through September 8, 2026.

NOT-DA-24-006

Specialties

Neurosciences

Substance Use Disorders

Others

Eligibility Requirements

For funding consideration, applicants must include “NOT-DA-24-006” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity